Medical Access and Reimbursement in Finland

Currently classified as a strictly controlled substance under Finland’s narcotics scheduling with no authorised medical use or routine reimbursement outside of approved clinical research. The government decree listing narcotics (Valtioneuvoston asetus huumausaineina pidettävistä aineista, 543/2008) enumerates tryptamines and related hallucinogens under controlled lists; possession, import, manufacture and distribution of psilocybin are penalised unless a specific research/authorisation permit is granted. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA (3,4‑methylenedioxymethamphetamine) and its analogues are listed under Finland’s narcotics decree and may only be handled lawfully under formal clinical trial or regulatory permit frameworks. #.

Esketamine nasal spray (Spravato) has a centralised marketing authorisation for the EU (European Commission authorisation following EMA positive opinion) for treatment‑resistant major depressive disorder (TRD) and related indications; the EMA product page records the EU marketing authorisation issued 18 December 2019. As an authorised medicinal product it can be marketed and supplied in Finland in line with EU authorisation and Finnish national medicine regulation. #.

Regulatory and reimbursement pathway in Finland: national clinical use and reimbursement are governed by Finnish authorities — the Finnish Medicines Agency (Fimea) oversees marketing authorisations/permits and specialised use arrangements, while reimbursement decisions and price‑related listings are handled by the Pharmaceuticals Pricing Board (Hila) and administered operationally by Kela. For any medicine to be reimbursed in Finland it must be included in Hila’s reimbursable medicines lists or be the subject of a confirmed reimbursement status; medicines requiring special permits follow the special‑permit and reimbursement rules described by Kela. Consequently, availability and reimbursement of Spravato in Finland depend on (a) marketing/authorisation and local distribution arrangements, (b) any required special permit procedures if applied, and (c) explicit Hila/Kela reimbursement decisions — in practice this results in supervised, clinic‑based administration and variable reimbursement that may require special permit or hospital invoicing pathways rather than automatic community pharmacy reimbursement. # #.

Clinical implementation/coverage nuance: Spravato is intended for administration under direct medical supervision with monitoring requirements per the product information (blood‑pressure checks, observation), which in many health systems creates a buy‑and‑bill or clinic‑administration model rather than simple outpatient dispensing. In Finland that clinical model typically places Spravato use in specialist psychiatric settings; reimbursement (partial or full) will depend on Hila’s specific reimbursement decision and whether the treatment is provided within publicly funded specialised care or via private providers with separate invoicing/authorisation procedures. Where reimbursement is not confirmed by Hila/Kela, institutions or individuals may pursue special permits or prior authorisation routes for individual patients. # #.

Ketamine is a legally approved medicinal anaesthetic and analgesic used in Finnish healthcare; as an approved anaesthetic agent it is used routinely in hospitals and its provision for anaesthesia and acute pain is part of reimbursable hospital care delivery. Clinical guidance in Finland recognises ketamine infusion or administration occasionally for rapid symptom relief in severe suicidal or treatment‑refractory depression in emergency contexts, but such psychiatric uses are generally off‑label and institutionally determined rather than covered by a specific reimbursable outpatient medicine listing. For example, Finnish clinical guidance and case law reference ketamine infusions in rapid relief settings for suicidal, non‑psychotic depression, indicating clinical but limited and situational psychiatric use. # #.

Reimbursement/administration nuance: routine reimbursement for ketamine when used as part of inpatient anaesthesia or other standard hospital services is captured within hospital funding and patient co‑payment rules. When ketamine is used off‑label in outpatient psychiatric programmes or private clinics for depression, reimbursement is less certain: such uses often require local institutional approval, explicit documentation of medical necessity, and may not be automatically reimbursable by Kela unless the medicine/treatment pathway is included in Hila/Kela reimbursement frameworks or provided under a public specialised care prior‑authorisation. Therefore ketamine’s legal status permits medical use and public‑sector coverage in conventional indications (anaesthesia, analgesia) but psychiatric/psychedelic use remains off‑label and typically outside standard reimbursed outpatient formularies. # #.

Currently classified as a strictly controlled substance under Finland’s narcotics scheduling; manufacture, import, export, sale and possession of DMT are criminal offences outside expressly authorised research or permit frameworks. Finnish courts and customs have treated ayahuasca/DMT plant preparations as subject to control where DMT content is present, resulting in seizures and legal action; lawful medical use is limited to authorised clinical research or special permits. # #.

5‑MeO‑DMT was explicitly added to Finland’s narcotics control by national amendment notified in 2023: Finland notified classification of 5‑MeO‑DMT as a narcotic and amended its narcotics decree to prohibit manufacture, import, export, sale and possession without a permit. As a result, 5‑MeO‑DMT is a scheduled substance with no authorised medical or reimbursable use outside approved clinical research or specific Fimea permits. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no established legal medical framework or reimbursement pathway in Finland for ibogaine; handling of ibogaine would require explicit regulatory authorisation and is otherwise prohibited. #.

Although plant material cases have seen judicial nuance, ayahuasca preparations containing DMT fall under Finland’s narcotics control where the active alkaloid is present; importation, sale or possession of DMT‑containing brews/plants has been subject to seizures and criminal proceedings. There is no authorised medical reimbursement pathway for ayahuasca; lawful uses are limited to approved research or rare, case‑by‑case permits. Concise statement: Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. # #.

Mescaline and mescaline‑containing cacti (e.g., peyote / San Pedro derivatives) are controlled under Finland’s narcotics decree; there is no routine medical authorisation or reimbursement for mescaline outside authorised clinical research or a specific, narrowly granted permit. Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #.

2C‑class phenethylamines (including 2C‑B / 2C‑X variants) are listed in Finland’s narcotics decree (government decree on narcotics 543/2008 and subsequent amendments) and are controlled substances. There is no authorised therapeutic/reimbursable medical use for 2C‑X compounds in Finland outside formally approved clinical trials or explicit permits. Standardised boilerplate: Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #.